# Transpara Breast AI at RSNA 2025: 29% More Cancers Found, 44% Less Reading Workload, and 11M+ Mammograms Processed

> At RSNA 2025, Transpara shows evidence-backed gains in detection and workload. From RCTs to DBT pre-reading, it helps programs find more cancers and cut reading time.

- Type: AI news
- Page: https://completeaitraining.com/news/transpara-breast-ai-at-rsna-2025-29-more-cancers-found-44/
- Published: 2025-12-01
- Updated: 2025-12-01
- Author: Jeroen Erne
- Jobs: Healthcare
- Reading time: 3 min

### Transpara Breast AI at RSNA 2025: Evidence, efficiency, and practical gains for breast imaging programs

ScreenPoint Medical is presenting the Transpara Breast AI suite at the 111th RSNA Annual Meeting (Nov 30-Dec 4, South Hall #4719). The suite brings Detection, Density, and Temporal Comparison into one workflow-ready platform that serves as a second set of eyes for radiologists. The focus is simple: detect cancers earlier, reduce reading burden, and improve screening program performance at scale.

#### Why this matters for your program

2025 has been a strong validation year for Transpara in both research and routine use. The platform has processed over 11 million mammograms and is deployed across 30+ countries. In the U.S., 40% of the Top 20 Best Hospitals Honor Roll recipients (US News & World Report, 2025) have selected Transpara.

Critically, Transpara is part of the only randomized controlled trials in Breast AI: the MASAI RCT in Sweden and the upcoming $16M PRISM RCT in the United States led by UCLA and UC Davis (starts early 2026). MASAI results published earlier this year reported a 29% increase in cancer detection and a 44% decrease in screen-reading workload with Transpara Detection compared to standard of care.

#### Risk assessment takes center stage

At RSNA, Transpara Risk-a 5-year, image-based breast cancer risk model-and Transpara Detection anchor new evidence: "Added Value of Breast Cancer Risk Prediction Versus Detection Over a Two-year Time Period with Mammography" (S5-SSBR02-4, Sunday, Nov 30, 2:30 PM, S406A). Findings show added value for precision care, with Transpara solutions outperforming both RSNA CAD and Mirai in this research. Transpara Risk is approved for investigational use only.

#### Where to see the data at RSNA 2025

- **Comparative performance on DBT** "Comparing Four Commercial AI Algorithms for Standalone Breast Cancer Detection on Digital Breast Tomosynthesis in a Dutch Population-based Screening Cohort" (T3-SSBR05-6, Tuesday, Dec 2, 9:30 AM, S406A). First head-to-head comparison on the same large dataset; Transpara Detection outperformed other commercial algorithms.
- **Interval cancers** "Potential of Artificial Intelligence to Detect Interval Breast Cancers" (M5A-SPBR, Monday, Dec 1, 12:15 PM, Learning Center). Suggests Transpara Detection may have supported earlier detection of 38% of interval cancers, especially those missed or underestimated by radiologists. Research conducted at Johns Hopkins Medicine.
- **Specificity gains using prior exams** "Use of Multiple Prior Exams Improves Specificity of an AI System for Breast Cancer Detection in a Retrospective Multi-site Validation" (T3-SSBR05, Tuesday, Dec 2, 9:30 AM, S406A). Higher specificity when prior exams are incorporated into Transpara analysis.
- **Real-world adoption** "Real-World Performance of an FDA-approved Artificial Intelligence Tool for Screening Mammography" (W5B-SPBR-3, Wednesday, Dec 3, 12:45 PM, Learning Center). Early implementation in a busy screening practice showed strong risk stratification and support for recall decisions. Research conducted at Johns Hopkins Medicine.
- **DBT pre-reading to reduce workload** "AI Pre-reading of Digital Breast Tomosynthesis: A Multi-site Validation of a Novel Imaging Biomarker for Confident Identification of Normal DBT Examinations" (R1-SSBR10, Thursday, Dec 4, 8:00 AM, S406A). A novel AI-driven biomarker identified ~one-third of normal DBT exams with a negative predictive value near 100%, enabling safe pre-reading and faster throughput.

#### Practical takeaways for clinical leaders

- **Screening efficiency:** Use AI pre-reading and risk stratification to route low-risk, normal-appearing DBT exams faster while preserving safety.
- **Reader workload:** Evidence points to meaningful reductions in screen-reading time without sacrificing detection, especially in high-volume programs.
- **Quality and specificity:** Incorporate multiple priors into AI analysis to improve specificity and reduce unnecessary recalls.
- **Program performance:** Combine Detection, Density, and Temporal Comparison to reinforce consistency across readers and sites.
- **Risk-guided pathways:** Image-based 5-year risk can enable personalized screening intervals and targeted prevention strategies (Transpara Risk is investigational).
- **Integration:** Deploy within enterprise workflows (PACS/VNA/RIS) to ensure AI outputs appear where radiologists already work.

#### Visit ScreenPoint Medical at RSNA

See Transpara Breast AI in action at Booth #4719 (South Hall). For details on sessions and logistics, visit the [RSNA Annual Meeting](https://www.rsna.org/annual-meeting?ref=completeaitraining.com) site. To schedule an online product overview after the show, visit [screenpoint-medical.com](https://screenpoint-medical.com/?ref=completeaitraining.com).

#### About ScreenPoint Medical

ScreenPoint builds AI-driven technology for the breast imaging continuum-supporting consistent reading, reducing uncertainty, and improving patient experience. Proven through research and real-world use, Transpara Breast AI is trusted by radiologists and programs worldwide.

---

This is the Markdown form of https://completeaitraining.com/news/transpara-breast-ai-at-rsna-2025-29-more-cancers-found-44/. The whole site is mapped at https://completeaitraining.com/llms.txt.
